SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently seeing increased market interest as investors focus on its critical role in the AI infrastructure supply chain, particularly regarding its liquid-cooled server solutions for NVIDIA platforms. While community sentiment remains divided between frustration over persistent range-bound trading and long-term optimism driven by record-level revenue and institutional accumulation, the stock is trending as participants weigh recent partnership news against concerns over profit margins.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant investor attention following a strategic partnership with Tesla that provides insurance discounts for FSD-enabled vehicles, fueling community speculation about data-driven growth. While the stock has experienced notable volatility and high short interest, bulls are focused on the company's AI-native insurance platform and its potential to scale rapidly against traditional carriers.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is gaining traction as investors focus on its proprietary real-time 3D sonar technology, which is increasingly critical for subsea infrastructure, defense, and maritime security. The community is actively discussing the stock's multi-bagger potential, high institutional interest, and the significant demand for its specialized equipment in global underwater operations.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is experiencing heightened investor interest driven by ongoing geopolitical tensions and the strategic necessity of domestic rare earth production for national defense and the semiconductor industry. Market participants are closely monitoring the upcoming Stillwater facility production ramp and potential government contract announcements, while actively debating the stock's volatility and the impact of institutional investments on its price action.

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals is capturing investor attention following consistently positive clinical data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis, which validates the potential of its DiffuSphere delivery technology. The community is actively discussing the company's progress toward Phase 2b development and its growing pipeline, while analysts remain focused on the stock's long-term commercial potential and upcoming milestones.

Telesat Corp. engages in the provision of satellite communications and consulting services. It operates through Geostationary (GEO) and Low Earth Orbit (LEO) segments. It is a global satellite operator, providing mission-critical communications solutions to support the requirements of sophisticated satellite users throughout the world and consists of 14 geostationary satellites and the Canadian payload on Viasat-1. The company was founded in 1969 and is headquartered in Ottawa, Canada.

Telesat Corp - Ordinary Shares - Class A

Telesat is trending due to significant momentum from the expansion of its Lightspeed constellation, specifically the inclusion of military Ka-band spectrum to meet rising global defense demand. Investors and traders are actively discussing the stock's potential for a re-rate, closely monitoring contract activity and the upcoming debt refinancing as key catalysts for growth.

Citi Trends, Inc. engages in the retail of urban fashion apparel, accessories, and home trends. It offers products under its Citi Steps and Red Ape brands. The company was founded in 1946 and is headquartered in Savannah, GA.

Citi Trends Inc

Citi Trends is currently trending as investors monitor its strategic turnaround plan, which includes store expansion and inventory management, alongside a raised fiscal outlook that has drawn significant attention from traders. The community is actively debating the company's long-term operational consistency and its ability to navigate current consumer spending headwinds.

ExlService Holdings, Inc. is an operations management and analytics company, which engages in providing business process management. It operates through the following segments: Insurance, Healthcare, Travel, Transportation, and Logistics, Finance and Accounting, Analytic, and All Other. The Insurance segment serves property and casualty insurance, life insurance, disability insurance, annuity, and retirement services companies. The Healthcare segment offers services related to care management or population health, payment integrity, revenue optimization, and customer engagement. The Travel, Transportation, and Logistics segment includes business processes in corporate and leisure travel such as reservations, customer service, fulfillment, and finance and accounting. The Finance and Accounting segment is comprised of procure-to-pay, order-to-cash, hire-to-retire, record-to-report, regulatory reporting, financial planning and analysis, audit and assurance, treasury, and tax processes. The Analytics segment consists of driving improved business outcomes for customers by generating data-driven insights. The All-Other segment is involved in banking, financial, utilities, and consulting services. The company was founded by Vikram Talwar and Rohit Kapoor in April 1999 and is headquartered in New York, NY.

ExlService Holdings Inc

Exlservice Hldgs Inc

Exlservice Holdings is currently in the spotlight following the announcement of an accelerated share repurchase agreement, coupled with its strategic expansion into agentic AI through an enhanced partnership with NVIDIA. The community is actively discussing these developments as indicators of long-term operational strength and growth potential within the enterprise AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)

BTIG Research reissued a "buy" rating and set a $8.00 price target on shares of AC Immune in a report on Monday...

AC Immune (NASDAQ:ACIU) Given Average Recommendation of "Hold" by Brokerages

Shares of AC Immune (NASDAQ:ACIU - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has...

AC Immune (NASDAQ:ACIU) Issues Earnings Results, Beats Estimates By $0.01 EPS

AC Immune (NASDAQ:ACIU - Get Free Report) released its earnings results on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of...

AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday

AC Immune (NASDAQ:ACIU) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised AC Immune from a "sell" rating to a "hold" rating in a research note on Saturday...

AC Immune (NASDAQ:ACIU) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of AC Immune from a "hold" rating to a "sell" rating in a research note on Saturday...

AC Immune (NASDAQ:ACIU) Stock Price Down 5.4% - Time to Sell?

AC Immune (NASDAQ:ACIU) Trading Down 5.4% - Here's Why...

Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4%

AC Immune (NASDAQ:ACIU - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227...

AC Immune (NASDAQ:ACIU) Trading Up 5% - Should You Buy?

AC Immune (NASDAQ:ACIU) Trading 5% Higher - Here's What Happened...

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Current Price	$3.13
Prev Close	$3.02
Open	$2.98
Dividend Yield	0.00%
50-Day Moving Average	$3.15
Beta	0.97
Avg. Volume	311,927.26
PE Ratio	-3.58

52-Week High	$4.00
52-Week Low	$1.43
Market Capitalization	$317.07M
EPS (Annual)	-$0.8419
Price to Book	3.38
Revenue Per Employee	$35,264.75

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACIU News

ACIUAC Immune SA